The Reason People Using Invokana Are Filing Law Suit Actions

by Terry Bryant

An increasing number of people using Invokana are filing law suit actions against the drug’s manufacturer, Johnson & Johnson, asserting that the medication is more dangerous than the company’s marketing would suggest. Canagliflozin, the drug’s trade name, is a new tactic in the fight against type 2 diabetes, but while it is effective at its listed purpose, there are serious adverse effects associated with the treatment. In some instances, these adverse effects can be fatal and extremely costly to correct.

Canagliflozin eliminates excess blood sugar by inhibiting the protein responsible for transporting it to the kidneys, where the body reabsorbs it. In effect, the cycle of releasing and storing blood glucose is broken, as the excess is excreted in urine. Studies have shown that canagliflozin can remove up to 120 grams of blood glucose a day, which is quite high. However, excreting the glucose places undue strain on the body, primarily because fluid is carried out with it.

Researchers believe that dehydration may be one reason why the drug produces an elevated risk of diabetic ketoacidosis, or DKA, in its users. DKA is a medical emergency, and occurs when insulin levels drop so much that the body can no longer process glucose adequately. The body then shifts to burning glycogen, and one of the natural byproducts of the process are ketones, which are acidic. If this process continues unabated, the victim’s blood acid level will spike, resulting in life-threatening symptoms, including coma.

More research will need to be done on Invokana, but law suit proceedings are already forming, and most claims involve people who experienced DKA after taking the medication. It is clearly something that Johnson & Johnson should have been aware of before releasing the drug on the market.